B+
Bull case
20%
Probability
Target price
$5.63
+132.6% vs current
CNTX
Context TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$2.30
-5.0% vs current
B-
Bear case
25%
Probability
Target price
$1.05
-56.6% vs current
AI sentiment snapshot
Latest data as of 2026-05-20
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+58.6
Score
AI commentary
This remains a cautious monitoring name. The strongest evidence is still the company’s own SEC filing trail, which points to June 2026 CTIM-76 interim data, Q3 2026 CT-202 first-patient dosing, and runway into mid-2027 [#10-Q-2026-05-06]. Coverage is low, the packet contains no useful analyst revision or target-change signal, social context is empty, and available peer candidates are only loose same-sector small-cap biotech checks rather than direct therapeutic comps. Conviction should therefore stay modest and tied to the upcoming clinical readout rather than to any broad thesis expansion.
RankAlpha Sentiment Codex - 2026-05-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventCTIM-76 Phase 1a interim data expected in June 2026High impact
The latest 10-Q says Context dosed the first patient in the CTIM-76 Phase 1 trial in January 2025, received FDA Fast Track designation for platinum-resistant ovarian cancer on April 2, 2026, and expects to share Phase 1a interim data in June 2026. This is the clearest near-term binary catalyst and the main potential thesis driver [#10-Q-2026-05-06].
2026-09-30eventCT-202 first-patient dosing targeted for Q3 2026High impact
The 10-Q states that Context submitted CT-202 to the Australian Bellberry Human Research Ethics Committee in March 2026 and expects to dose the first patient in the Phase 1 trial in the third quarter of 2026. Hitting that timing would support the multi-asset platform story; delay would reinforce execution skepticism [#10-Q-2026-05-06].
2027-06-30catalystRunway into mid-2027, but financing remains a standing overhangHigh impact
The 10-Q says existing cash is expected to fund the Phase 1a dose-escalation portions of CTIM-76 and CT-95, CT-202 trial initiation, and operations into mid-2027, while also warning that substantial additional capital will be needed. That keeps dilution terms and financing access central to the equity case [#10-Q-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-20 • Updated nightlySource: Internal modelMethodology